BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

IN THE CLAIMS:

Please amend the claims as follows:

1-16. (canceled)

17. (currently amended) A method for screening compounds for receptor tyrosine kinase (RTK) agonists or RTK antagonists comprising:

(a) crystallizing a modified RTK polypeptide, said modified RTK polypeptide having kinase activity and comprising RTK kinase domain α helix D linked to RTK kinase domain α helix E by a truncated RTK kinase insert domain (KID);

(b) obtaining crystallography coordinates for said modified RTK polypeptide;

(c) applying said crystallography coordinates for said modified RTK polypeptide in order to generate a model of said modified RTK polypeptide ~~suitable~~ for use in designing ~~molecules~~ compounds that will act as agonists or antagonists to said modified RTK polypeptide; and

(d) applying an iterative process whereby various molecular structures are applied to said model to identify agonists or antagonists to said modified RTK polypeptide.

18. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 50 residues from the KID.

19. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 60 residues from the KID.

20. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of the highly charged residues from the KID.

21. (previously presented) The method of claim 17 wherein said truncated kinase insert domain linking said α helix D to said α helix E is of a sufficient length so as

to allow said helices to maintain appropriate conformation associated with competent kinase structure.

22. (currently amended) The method of claim 17 wherein said RTK polypeptide is a member of the platelet derived growth factor receptor (PDGFR) family.

23. (currently amended) The method of claim 22 wherein said PDGFR member is selected from the group consisting of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 ~~VEFGR-2~~, PDGFR-α, PDGFR-β, stem cell growth factor receptor (c-kit), and colony stimulating factor-1 receptor (CSF-1R/c-fms).

24. (previously presented) The method of claim 22 wherein said RTK polypeptide is selected from the group consisting of insulin receptor (IRK), fibroblast growth factor receptor-1 (FGFR-1), and VEGFR-2.

25. (previously presented) The method of claim 17 wherein said RTK polypeptide is VEGFR-2.

26. (previously presented) The method of claim 17 wherein said modified RTK polypeptide comprises VEGFR2Δ50 polypeptide of SEQ ID NO: 5.